Given the remarkable therapeutic outcomes of the CYSLTR1 antagonist montelukast in the IMQ-induced psoriasis model, our initial approach involved establishing a psoriasis model in CYSLTR1 KO mice to elucidate the role of CYSLTR1 in the progression of psoriasis. The gene discussed is CYSLTR1; the disease is psoriasis.